Eli Lilly's weight-loss pill wins EU drug regulator's backing
What it is about
Who published it, and when
2 reports left out of the cascade - too little in common with the story to place
How it spread - 8 original reports
Fri, 16 October 2026
4 reports- Google News - Europe query10:09first to report
Eli Lilly's weight-loss pill wins EU drug regulator's backing Reuters
- Google News - Europe query10:27
Eli Lilly’s weight-loss pill wins backing in Europe The Mighty 790 KFGO
- Google News - Europe query10:30
Eli Lilly’s weight-loss pill wins backing in Europe WHBL News
- Google News - Europe query15:30
Lilly's obesity pill, RevMed's pancreatic cancer breakthrough among slew of CHMP endorsements in Europe Fierce Pharma
Sun, 18 October 2026
1 report- Google News - Europe query13:30
European Union Regulators Recommend Approval For Eli Lilly Weight Loss Pill Yahoo Finance
Thu, 29 October 2026
3 reports- Google News - Top Stories10:13
Eli Lilly blows past estimates, hikes sales outlook on resilient Zepbound and Mounjaro demand CNBC Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio Eli Lilly Eli Lilly (NYSE:LLY) reports upbeat Q3 2026, guides for strong full-year sales Yahoo Finance Lilly Raises Sales Guidance, Widening Its Lead in Obesity Market Bloomberg Eli Lilly Revenue Climbs on Demand for Mounjaro, Zepbound WSJ
- El País (Spain)13:37
La mayor farmacéutica del mundo por capitalización bursátil dispara los ingresos un 39%, por encima de lo esperado por el mercado
- Google News - Top Stories17:16
Earnings live updates: Eli Lilly stock pops as strong GLP-1 drug demand lifts results, ServiceNow stock plunges Yahoo Finance We're raising our price target on Eli Lilly as the obesity-drug boom rolls on CNBC Eli Lilly Stock Jumps on Monster Earnings Powered by Mounjaro and Zepbound Barron's Eli Lilly lifts revenue outlook as weight-loss shots offset Foundayo sales miss, shares jump Reuters Eli Lilly profits surge on demand for weight-loss drugs Financial Times